COVID-19 is the infectious disease caused by the new coronavirus (SARS-CoV-2) identified in late 2019. COVID-19 is affecting many countries globally and has been declared a pandemic by the World Health Organization (WHO).
“The partnership with the UK government and the advanced discussions with the EC validate our inactivated vaccine approach and recognize the strong track record and capabilities we have built in the last fifteen years.”
Thomas Lingelbach, CEO of Valneva
About the vaccine candidate VLA2001
- Adjuvanted with Alum and CpG 1018
- Whole virus candidate
- Vero-cell based
- Using the manufacturing platform of Valneva’s commercial Japanese encephalitis (JE) vaccine
Valneva initiated Phase 1/2 clinical study in December 2020
The VLA2001-201 study is a randomized, double blind trial evaluating the safety and immunogenicity for three dose levels in approximately 150 healthy adults. The primary endpoint read-out will be two weeks after completion of the two-dose primary immunization (day 0, 21). Subject to analysis of this data, additional trials are expected to commence immediately thereafter. The Company currently plans to include more than 4,000 participants in additional trials, which it believes could support an initial regulatory approval as soon as the fourth quarter of 2021.
Agreement with the UK & discussions with the EC
In September 2020, Valneva announced a partnership with the UK government for its inactivated COVID-19 vaccine, VLA2001. Under the agreement, if vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021. UK Government then has options over an additional 130 million doses, across 2022 to 2025. UK government is also investing up-front in the scale up and development of the vaccine.
In January 2021, Valneva announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of VLA2001.
Valneva’s UK-based manufacturing facilities
The facility in Livingston has been producing FDA/EMA/MHRA approved commercial-grade travel vaccines for more than a decade. It will be the production hub for Valneva’s COVID-19 vaccine candidate. The UK government funding will allow Valneva to expand the site’s capacity for drug
substance production, accelerate clinical development
and increase the number of jobs at the Livingston facility.
Valneva’s fill and finish capacities in Sweden
Valneva’s facility in Solna, dedicated to the production of the Company’s cholera vaccine, is expanding its capacity in order to provide full fill and finish operations for the VLA2001 vaccine.
FAQ about VLA2001
- VLA2001 is a Vero-cell based, highly-purified inactivated whole virus vaccine candidate.
- VLA2001 is the first inactivated COVID-19 vaccine in clinical development in Europe.
- The inactivated vaccine is a proven approach that has been used for decades.
- An inactivated SARS-CoV-2 vaccine would be suitable for wide deployment including particularly vulnerable populations.
- Processes and infrastructures for the inactivated approach are well established.
- Valneva’s vaccine candidate is based on the same manufacturing platform the Company already uses to produce its FDA/EMA/MHRA approved JE vaccine.
- VLA2001 combined with Alum and Dynavax’s FDA-approved adjuvant CpG 1018 is expected to induce a strong immune response and has the potential to generate high titers of neutralizing antibodies.
- Valneva’s inactivated SARS-CoV-2 vaccine is expected to have a two-dose regimen.
- VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees centigrade).
 Inactivated Viral Vaccines. Vaccine Analysis: Strategies, Principles, and Control. 2014 Nov 28 : 45–80. Published online 2014 Nov 28. doi: 10.1007/978-3-662-45024-6_2 PMCID: PMC7189890
Valneva is working as quickly as possible to develop a safe and effective vaccine against COVID-19 and VLA2001 will be tested in clinical trials to confirm safety and effectiveness against this disease. Valneva has a very solid database on the safety of this inactivated virus approach from its JE vaccine, which has been FDA/EMA/MHRA approved for over a decade.
This vaccine entered a Phase 1/2 clinical study in December 2020. The Company currently plans to include more than 4,000 participants in additional trials. Due to the extensive history and success of inactivated virus vaccines, Valneva believes that VLA2001 has a high likelihood of a first regulatory approval in the fourth quarter of 2021, subject to the appropriate regulatory authority requirements.
Learn more about Valneva’s COVID 19 vaccine study here: https://www.ukcovid19study.com/
Valneva has reached agreement in principle with the UK government to provide up to 190 million doses of its SARS-CoV-2 vaccine across 2021 to 2025. Valneva is also in advanced discussions with the EC for the supply of up to 60 million doses of VLA2001. As part of its broader COVID-19 response, Valneva is building capacity to deliver up to 200 million doses per year.
Valneva Stands with Science
Additional information about COVID-19
Related Press Releases
- Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
- Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
- Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government
- Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program
- Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19